Antiviral resistance in influenza viruses--implications for management and pandemic response

N Engl J Med. 2006 Feb 23;354(8):785-8. doi: 10.1056/NEJMp068030.
No abstract available

MeSH terms

  • Amantadine / pharmacology
  • Amantadine / therapeutic use
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Disease Outbreaks* / prevention & control
  • Drug Resistance, Viral*
  • Humans
  • Influenza A Virus, H3N2 Subtype / drug effects*
  • Influenza A Virus, H3N2 Subtype / genetics
  • Influenza A Virus, H3N2 Subtype / physiology
  • Influenza, Human / drug therapy*
  • Influenza, Human / epidemiology
  • Mutation
  • Neuraminidase / antagonists & inhibitors*
  • Nucleic Acid Synthesis Inhibitors / pharmacology
  • Nucleic Acid Synthesis Inhibitors / therapeutic use
  • Rimantadine / pharmacology
  • Rimantadine / therapeutic use
  • Viral Matrix Proteins / antagonists & inhibitors*
  • Virus Replication / drug effects

Substances

  • Antiviral Agents
  • M2 protein, Influenza A virus
  • Nucleic Acid Synthesis Inhibitors
  • Viral Matrix Proteins
  • Rimantadine
  • Amantadine
  • Neuraminidase